Exopharm

Ian Dixon

Managing Director & Founder

PhD, MBA, MAICD

Dr Ian Dixon has a PhD in biomedical engineering from Monash University, an MBA from Swinburne University and professional engineering qualifications.

Ian has been successful in translating technology challenges into valuable businesses and respected intellectual property.

Ian is a co-inventor of Exopharm’s LEAP manufacturing technology and a co-inventor of Fortrexo, part of Exopharm’s EEV pipeline.

Ian brings to Exopharm an extensive technical, commercial and entrepreneurial background.

Before founding Exopharm in 2013, Ian co-founded Cynata Inc, the owner of the Cymerus stem cell technology now being commercialised by ASX-listed clinical-stage Cynata Therapeutics Ltd (ASX:CYP).

He is also non-executive director of NYRADA Inc. (ASX:NYR), co-inventor of Nyrada PCSK9 inhibitor drug NYX-330, and founder and investor of Cardio Therapeutics Pty Ltd.

Ian was previously a founding director of Sydney-based Noxopharm Ltd (ASX:NOX) and non-executive director of Melbourne unlisted company Cell Therapies Pty Ltd. Ian currently serves as a part-time director of Medigard Ltd (ASX:MGZ).

David Parker

Non-executive Director

B.Comm, SAFin

Mr David Parker has over sixteen years’ experience as a corporate advisor and investment manager. He has served as a director or company secretary for a number of ASX-listed companies, having taken several from private companies to listed entities.

David is an employee of Alto Capital, a stockbroking and corporate advisory firm which is licensed to provide financial advice to retail and wholesale investors. David is also the director of Cobblestones Corporate, which provides boutique corporate advisory and company secretarial consulting services to pre-IPO and ASX listed entities.

David is a Senior Associate (and member since 2001) of the Financial Services Industry of Australian (FINSIA). He has a Bachelor of Commerce from Curtin University and has completed a Graduate Diploma of Applied Corporate Governance from the Governance Institute.

David was previously a non-executive director and company secretary of Aurora Labs Ltd (ASX:A3D) and non-executive director of Pacific Ord Ltd (ASX:SYT).

Sinead Teague

Company Secretary

MSc, LLB

Ms Sinead Teague has served as a company secretary across a number of ASX-listed and unlisted entities across a number of industry sectors. She is currently a Company Secretary with the Automic Group.

Sinead holds a Masters in Management and Corporate Governance and a Degree in Law with Government and is an associate member of the Governance Institute of Australia.

Jason Watson

Non-Executive Director, Chair

LL.B, B. Comm

Mr Jason Watson has board and advisory experience acting with small and medium-sized enterprises, research institutes and listed companies in the life sciences and other sectors. In particular, he has assisted companies in developing, commercialising and transacting technologies through significant biotechnology licensing deals.

Jason is principal of Elementary Law, a legal practice based in Melbourne, Australia. His practice focuses on assisting clients to achieve the best outcomes for their patents and innovations, including through corporate fundraising, protection strategies, licensing and commercialisation. In this capacity, Jason has been recognised in the Intellectual Asset Magazine Patent 1000 independent list of The World’s 1000 Leading Patent Professionals.

Jason has expertise in relation to complex transactions, including establishing multi-party engagements, research and consultancy contracts and negotiating and implementing clinical trial, licensing, assignment, manufacturing, shareholding and other commercial arrangements.

Jason has a Bachelor of Laws with Honours and a Bachelor of Commerce.